Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia

Drugs of Today

Volumn 45, Issue 2, 2009, Pages 93-99

  Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; NPLATE; PEGINTERFERON ALPHA2B; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CATARACT; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; HEADACHE; HEPATITIS C; HEPATOBILIARY DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIMB PAIN; LUNG EMBOLISM; NAUSEA; PERIPHERAL EDEMA; RHINOPHARYNGITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

BENZOIC ACIDS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HUMANS; HYDRAZINES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA;

EID: 66249090142     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.2.1322479     Document Type: Article

References (23)

1. Jurk, K., Kehrel, B.E. Platelets: Physiology and biochemistry. Semin Thromb Hemost 2005,31(4): 381-92.
2. Panzer, S., Rieger, M., Vormittag, R., Eichelberger, B., Dunkler, D., Pabinger, I. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007,37(10): 814-9.
3. Panzer, S. New therapeutic options for adult chronic immune thrombocytopenic purpura: A brief review. Vox Sang 2008, 94(1): 1-5.
4. Sailer, T., Lechner, K., Panzer, S., Kyrle, P.A., Pabinger, I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006, 91(8): 1041-5.
5. Panzer, S., Seel, E., Brunner, M. et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006, 77(6): 513-7.
6. Peck-Radosavljevic, M., Zacherl, J., Wichlas, M. et al. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. Eur J Gastroenterol Hepatol 1999, 11(2): 151-6.
7. Peck-Radosavljevic, M., Wichlas, M., Zacherl, J. et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000, 95(3): 795-801.
8. Kuter, D.J. New thrombopoietic growth factors. Blood 2007, 109(11): 4607-16.
9. Archimbaud, E, Ottmann, O.G., Yin, J.A. et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999, 94(11): 3694-701.
10. Fanucchi, M., Glaspy, J., Crawford, J. et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336(6): 404-9.
11. Li, J., Yang, C, Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kuter, D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98(12): 3241-8.
12. Jenkins, J.M., Williams, D., Deng, Y. et al. Phase 7 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109(11): 4739-41.
13. Erhardt, J., Erickson-Miller, C.L., Tapley, P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 2004,104(11, Pt. 2): Abst 3888.
14. Stasi, R., Evangelista, M.L., Amadori, S. Novel thrombopoietic agents: A review of their use in idiopathic thrombocytopenic purpura. Drugs 2008, 68(7): 901-12.
15. Bussel, J.B., Cheng, G., Saleh, M.N. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357(22): 2237-47.
16. Bussel, J.B., Provan, D., Shamsi, T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura-. A randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9664): 641-8.
17. Psaila, B., Bussel, J.B., Linden. M.D. et al. In vivo effects of eltrombopag on human platelet function. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 1301.
18. Cheng, G., Saleh, M.N., Bussel, J.B. et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: Results of a phase III, double-blind, placebo-controlled study (RAISE). Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 400.
19. Saleh, M.N., Bussel, J.B., Cheng, G. et al. Eltrombopag is efficacious in patients with refractory chronic idiopathic thrombocytopenic purpura (UP) - Data from the EXTEND Study. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008,112(11): Abst 401.
20. Cheng, G., Bussel, J.B., Saleh, M.N. et al. Eltrombopag delivers clinical benefit in chronic idiopathic thrombocytopenic purpura (ITP) patients not achieving platelet counts 50,000/μL Data from the EXTEND Study. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008,112(11): Abst 3430.
21. Bussel, J.B., Cheng, G., Saleh, M.N.etal. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008,112(11): Abst 3432.
22. McHutchison, J.G., Dusheiko, G., Shiftman, M.L. et al.; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357(22): 2227-36.
23. Schmid, M., Kreil, A., Jessner, W., et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005, 54 (7): 1014-20.